Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston2Department of Ophthalmology, Weill Cornell Medical College, New York, New York.
Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston.
JAMA Ophthalmol. 2015 Aug;133(8):881-7. doi: 10.1001/jamaophthalmol.2015.1119.
Somatic mutations in BAP1 (BRCA1-associated protein 1 gene) are frequently identified in uveal melanoma. To date, the role of germline BAP1 mutations in uveal melanoma has not been characterized.
To characterize the clinical phenotype of uveal melanoma in patients with germline BAP1 mutations.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study at an academic ophthalmology referral center among 507 patients with uveal melanoma who consented for collection of blood samples. The study dates were June 22, 1992, to December 14, 2010.
Clinical characteristics of uveal melanoma and the development of metastases. BAP1 gene sequencing from blood samples of patients with uveal melanoma was correlated with clinical characteristics.
Of 507 blood samples analyzed, 25 patients (4.9%) exhibited 18 BAP1 polymorphisms, of which 9 were novel. Computational analyses predicted that 8 BAP1 mutations in 8 patients (1.6%) were likely to result in damaged BAP1 protein. Five of these 8 mutations were novel. These 8 patients were compared with 482 patients in whom no BAP1 polymorphisms were identified. In univariate analyses, patients with germline BAP1 mutations exhibited larger tumor diameters (mean, 15.9 vs 12.3 mm; P = .004) and higher rates of ciliary body involvement (75.0% vs 21.6%, P = .002) and metastases (71.4% vs 18.0%, P = .003) compared with control subjects. Patients with germline BAP1 mutations exhibited increased frequency of family history of cancer (100% vs 65.9%, P = .06), particularly cutaneous melanoma (62.5% vs 9.9%, P < .001) and ocular melanoma (25.0% vs 1.9%, P = .01). No differences were identified in age at diagnosis, sex, history of other malignant neoplasm, presenting visual acuity, distance of the tumor from the optic nerve or fovea, iris involvement, extrascleral extension, or tumor pigmentation. Germline BAP1 mutations increased risk of metastasis independent of ciliary body involvement (P = .02). Germline BAP1 mutation approached significance as an independent risk factor for metastasis (P = .09).
These data suggest that germline BAP1 mutations occur infrequently in uveal melanoma and are associated with larger tumors and higher rates of ciliary body involvement, 2 known risk factors for metastasis.
BAP1(BRCA1 相关蛋白 1 基因)体细胞突变在葡萄膜黑色素瘤中经常被发现。迄今为止,胚系 BAP1 突变在葡萄膜黑色素瘤中的作用尚未被描述。
描述胚系 BAP1 突变患者葡萄膜黑色素瘤的临床表型。
设计、地点和参与者:在一家眼科会诊中心对 507 名同意采集血液样本的葡萄膜黑色素瘤患者进行回顾性队列研究。研究日期为 1992 年 6 月 22 日至 2010 年 12 月 14 日。
葡萄膜黑色素瘤的临床特征和转移的发展。对来自葡萄膜黑色素瘤患者血液样本的 BAP1 基因进行测序,并与临床特征相关联。
在分析的 507 个血液样本中,25 名患者(4.9%)表现出 18 种 BAP1 多态性,其中 9 种是新的。计算分析预测,8 名患者的 8 种 BAP1 突变可能导致 BAP1 蛋白受损。这 8 种突变中有 5 种是新的。将这 8 名患者与 482 名未发现 BAP1 多态性的患者进行比较。在单因素分析中,与对照组相比,胚系 BAP1 突变患者的肿瘤直径更大(平均值,15.9 比 12.3 毫米;P = .004),睫状体受累的发生率更高(75.0%比 21.6%;P = .002)和转移(71.4%比 18.0%;P = .003)。与对照组相比,胚系 BAP1 突变患者癌症家族史的发生率更高(100%比 65.9%;P = .06),尤其是皮肤黑色素瘤(62.5%比 9.9%;P < .001)和眼部黑色素瘤(25.0%比 1.9%;P = .01)。两组患者的诊断时年龄、性别、其他恶性肿瘤史、首发视力、肿瘤距视神经或黄斑的距离、虹膜受累、眼外延伸或肿瘤色素沉着均无差异。BAP1 胚系突变独立于睫状体受累增加了转移的风险(P = .02)。BAP1 胚系突变成为转移的独立危险因素(P = .09)。
这些数据表明,胚系 BAP1 突变在葡萄膜黑色素瘤中很少发生,与更大的肿瘤和更高的睫状体受累率相关,这是两种已知的转移危险因素。